Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
DGKA, Active (D21-10BG)

DGKA, Active (D21-10BG)

  • $226.00


Description : Recombinant full-length human DGKA was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species : Human

Tag:  GST tag

Expression System:  Sf9 insect cells using baculovirus

Sequence:  Full length

Genbank Number:  NM_001345

Specific Activity : Sample Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity : Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping : Store product at -70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications : Kinase Assay

Molecular Weight :  105 kDa

Gene Aliases :  DAGK; DAGK1; DGK-alpha

Formulation :  50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Scientific Background : Diacylglycerol kinase alpha (DAG kinase alpha) is a member of the eukaryotic diacylglycerol kinase family. Upon cell stimulation converts the second messenger diacylglycerol into phosphatidate, initiating the resyn-thesis of phosphatidylinositols and attenuating protein kinase C activity. Involved in hepatocellular carcinoma progression through regulation of the Ras/Raf/MEK/ERK pathway. The DGKα/atypical PKC/β1 integrin signaling pathway is required for matrix invasion of breast carcinoma cells.

References : 
1. Takeishi, K. et al. (2012). Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. J. Hepatol. 57, 77–83.

2. Rainero, E. et al. (2014). The diacylglycerol kinase alpha/atypical PKC/beta1 integrin pathway in SDF-1alpha mammary carcinoma invasiveness. PLoS ONE 9:e97144.

3. Sakane F, et al. (2016). Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases: An Update. Front Cell Dev Biol. 4:82.

Product Sheets: (by Lot #):



Research Areas: Apoptosis/Autophagy, Cancer, Cardiovascular Disease, Cell Cycle, Inflammation, PKA/PKC Pathway,